Source comparison
Athletic Performance Peptides 2026 Update: Comparison Table
TB-500 Upregulates actin; promotes angiogenesis and tissue repair Phase 2 RCT: 22% faster recovery in soft tissue injuries (Journal of Applied Physiology, Nov 2025) Prohibited (Jan 2026) 5mg twice weekly for 4–6 weeks Strongest clinical data for recovery; now
This comparison does not assign a generated winner or score.
- TB-500
- Upregulates actin; promotes angiogenesis and tissue repair
- Phase 2 RCT: 22% faster recovery in soft tissue injuries (Journal of Applied Physiology, Nov 2025)
- Prohibited (Jan 2026)
- 5mg twice weekly for 4–6 weeks
- Strongest clinical data for recovery; now unavailable for competitive athletes but remains accessible for research
- BPC-157
- Gastric cytoprotective; promotes tendon and ligament healing via angiogenesis
- Animal models show 35% faster tendon repair; limited human trials
- 250–500mcg daily subcutaneous
- Promising preclinical data but lacks Phase 3 human trials; widely used in research settings
- Ipamorelin + CJC-1295
- GH secretagogue; stimulates pulsatile growth hormone release
- Phase 2 trial: 14% lean muscle retention during caloric deficit (Stanford, 2025)
- Permitted (not prohibited)
- Ipamorelin 200–300mcg + CJC-1295 100mcg, 5 days/week
- Evidence supports recovery and body composition; legal for competitive use as of 2026
- MK-677
- Oral GH secretagogue; increases IGF-1
- Observational studies show improved sleep quality and appetite; no RCTs for athletic performance
- 10–25mg daily, oral administration
- Convenience of oral dosing; lacks rigorous athletic performance trials
- AOD-9604
- Fragment of GH; promotes lipolysis without affecting blood glucose
- Small trials show 2–3% body fat reduction over 12 weeks; no athletic performance data
- 300mcg daily subcutaneous
- Fat loss mechanism supported; banned despite limited performance-enhancement evidence